FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB00-716-D RPI NO. 600.016	<b>Serial No.</b> 10/043,951
OIF ( DEC 0 6 2002 8	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant:	RECEIVED
(A) Asia			TECH CENTER 1600/2900
		Filing Date: 01/11/02	<b>Group:</b> 1632

# **U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclas s	Filing Date if Appropriat e

# **FOREIGN PATENT DOCUMENTS**

						Translation
	Document Number	Date	Country	Class	Subclass	
1. 1/	WO 97/26270	July 24, 1997	PCT			

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

2.	PL	Grotli et al., "2'-O-(Carbamoylmethyl) oligoribuncleotides," <u>Tetrahadron</u> 55:4299-4314 (1999)
3.	PL	Grotli et al., "Protection of the Guanine Residue During Synthesis of 2'-O-alkyl-guanosine Derivatives," J. Chem. Soc., Perkin Trans, 1:2779-2788 (1997)
4.	PL	Karpeisky et al., "2'-O-Methylthiomethyl Modifications in Hammerhead Ribozymes," Nucleosides & Nucleotides 16:955-958 (1997)
5.	PL	Wada et al., "Regioselective Protection of the 2'Hydroxyl Group of N-Acyl-3',5'-O-di(t-butyl)silanediylnucleoside Derivatives by Use of t-BuMgCl and 2-(Trimethylsilyl)ethoxymethyl Chloride," <u>Tetrahedron Letters</u> 36:1683-1684 (1995)

(F	
EXAMINER ALLASON	DATE CONSIDERED 8-13-13

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

# KECFIVED

OCT 0 1 2002 **FORM PTO-1449** TECH (ITSTDepartme) 13 (1) Commerce Patent and Trademark Office Atty. Docket No. Serial No. (Rev. 2-32) MBHB00,716-D 10/043,951 RPI NO. 600.016 ÍATION DISCLOSURE EMENT BY APPLICANT . (Use several sheets if necessary) Applicant: Beigelman, et al. Filing Date: Group:

#### **U.S. PATENT APPLICATION DOCUMENTS**

01/11/02

1632

Examiner Initial	Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate

#### **U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

		The second of th
PL	1.	Corey and Hopkins, "Diisopropylsilyl Ditriflate and Di-tert-Butylsilyl Ditriflate: New Reagents for the Protection of Diols," Tetrahedron Letters 23:4871-4874 (1982)
	2.	Furusawa et al., "Synthesis and Restricted Conformation of 3', 5'-Q-(Di-t-butylsilanediyl) Ribonucleosides," Chemistry Letters 97-100 (1990)
	3.	Larsen et al., "A New and Easy Synthesis of Silylated Furanoid Glycals in One Step from Nucleosides," Synthesis 1037-1038 (1994)
	4.	Markiewicz, "Tetraisopropyldisiolaxane-1, 3-diyl, a Group for Simultaneous Protection of 3'- and 5'- Hydroxy Functions of Nucleosides," J. Chem. Research (S) 24-25 (1979)
V	5.	Trost and Caldwell, "The Di-t-Butylsilylene Protecting Group for Diols," <u>Tetrahedron Letters</u> 22:4999-5002 (1981)
PL	6.	Wu and Pitsch, "Synthesis and Pairing Properties of Oligoribonucleotide Analogues Containing a Metal- binding Site Attached to β-D-Allofuranosyl Cytosine," Nucleic Acids Research 26:4315-4323 (1998)

EXAMINER	DATE CONSIDERED
THE MANNET SALE	17,20

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHNEN HULBERT & BERGHOFF 300 SOUTH WACKER DRIVE CHICAGO, ILLINOIS 60606 TELEPHONE (312) 913-0001

<b>FORM</b>	PTO-1449
(Rev. 2	2-32)

# U.S. Department of Commerce **Patent and Trademark Office**

Atty. Docket No.					
MBHB00,716-D					
PPI NO 600 016					

Serial No. 10/043,951

# INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use several sheets if necessar ECEIVED

MAY 0 6 2002

**TECH CENTER 1600/2900** 

Applicant:	
Reigelman	et

Filing Date: 01/11/02

Group: 1632

# **U.S. PATENT APPLICATION DOCUMENTS**

Exam Init	 	Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	 *	09/406,643	9/27/99	Ludwig et al.			

# **U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
PL	*	4,987,07	1 01/22/91	Cech et al.			
	*	5,631,36	05/20/97	Usman et al.			
	*	5,849,90	2 12/15/98	Arrow et al.			
	*	5,891,68	3 04/06/99	Usman et al.			
T V	*	5,962,67	5 10/05/99	Beiglelman et al.			
PL	*	5,998,20	3 12/07/99	Matulic-Adamic et al.			

#### **FOREIGN PATENT DOCUMENTS**

								Translation
			<b>Document Number</b>	Date	Country	Class	Subclass	
	PL	*	6067492		Japanese (Furusawa)			
		*	10226697	_	Japanese (Furusawa)			
		*	WO 99/55857	11/04/99	WO (Beigelman et al.)			
Γ	V	*	WO 99/16871	04/08/99	WO (Eckstein et al.)		<del> </del>	
	PL	*	WO 98/28317	07/02/98	WO (Karpiesky et al.)		<del> </del>	F

· · · · · · · · · · · · · · · · · · ·			
EXAMINER Soft also	112	DATE CONSIDERED	
1/1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

lue	v. 2-3	)		
		1	P	Ž

**FORM PTO-1449** 

U.S. Department of Commerce **Patent and Trademark Office**  Atty. Docket No. MBHB00,716-D RPI NO. 600.016 Serial No. 10/043,951

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets-if necessary) RECEIVED

MAY 0 6 2002

Applicant:

Beigelman, et al.

TECH CENTER 1600/2900 €

Filing Date: 01/11/02

Group: 1632

1/2	*	WO 98/58057	12/23/98	WO (Ludwig et al.)		 
	*	WO 98/58058	12/23/98	WO (Ludwig et al.)		l

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

R	*	Agrawal, "Antisense oligonucleotides: towards clinical trials," <i>Trends Biotech.,</i> 14, 376-387 (1996)
	*	Beaucage and Iyer, "Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach," <i>Tetrahedron</i> , 48, 2223-2311 (1992)
	*	Beaudry et al., "In vitro selection of a novel nuclease-resistant RNA phosphodiesterase," Chemistry and Biology, 7, 323-334 (2000)
	*	Beigelman et al., "Synthesis of 2'-modified nucleotides and their incorporation into hammerhead ribozymes," Nucleic Acids Research 23(21):4434-4442 (1995)
	*	Bhat, V. et al., "A simple and Convenient Method for the Selective N-Acylations of Cytosine Nucleosides," <i>Nucleosides &amp; Nucleotide</i> , 8(2), 179-83 (1989)
	*	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," Biochemistry 35:14090-14097 (1996) (volume no. mistakenly listed as 6)
	*	Cech, "Ribozymes and Their Medical Implications," JAMA 260:3030-3034 (1988)
	*	Chaix et al., "Sold phase synthesis of the 5'half of the initiator 1-RNA from <i>B. subtilis</i> ," Nucleic Acids Research, 17, 7381-7393 (1992)
	*	Christoffersen and Marr, "Riobozymes as Human Therapeutic Agents," <u>J. Med. Chem.</u> 38:2023-2037 (1995) (also referred to as Christofferson and Marr)
	*	Cook et al., "Characterization of HIV-1 REV protein: binding stoichiometry and minimal RNA substrate," <i>Nucleic Acids Research</i> , 19, 1577-1583 (1991)
V	*	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," Advances in Pharmacology 40:1-49 (1997)
PC	*	Crooke, "Antisense Therapeutics," <u>Biotechnology and Genetic Engineering Reviews</u> 15:121-157 (1998)

EXAMINER /	DATE CONSIDERED
	DATE CONSIDERED
91 at un 1 Ho	1 8-13-07
1700000	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



FORM PTO-1449 (Rev. 2-32)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. MBHB00,716-D RPI NO. 600.016

Serial No. 10/043,951

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(Use-several-sheets-if-necessary RECEIVED

MAY 0 6 2002

TECH CENTER 1600/2900

Appl	icant:
Daia	ممصام

Beigelman, et al.

**Filing Date:** 01/11/02

**Group:** 1632

	2	*	Delihas et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," Nature Biotechnology 15:751-753 (1997)
	ſ	*	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," Proc. Natl. Acad. Sci. USA 89:504-508 (1992)
		*	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," Nature 365:566-568 (1993)
		*	Francklyn and Schmimel, "Aminoacylation of RNA minihelics with alanine," <i>Nature</i> , 337, 478-481 (1989)
		*	Gait et al., "Ch. 2 - Oligoribonucleotide synthesis," in <u>Oligonucleotides and Analogues: A Practical Approach</u> , edited by Eckstein, IRL Press, Oxford, pp. 25-48 (1991)
		*	Gold, "Posttranscriptional Regulartory Mechanisms in Escherichia Coli," Annu. Rev. Biochemistry, 57, 199-233 (1988)
		*	Hobbs and Eckstein, "A General Method for the Synthesis of 2'-Azido-2'-deoxy- and 2'-Amino-2'-deoxyribofuranosyl Purines," J. Org. Chem. 42:714-719 (1977)
		*	Ikehara and Maruyama, "The Total Synthesis of an Antibiotic 2'-Amino-2'deoxyguanosine," <i>Chem. Pharm. Bull.</i> , 26, 240-244 (1978)
		*	Ikehara et al., "Synthesis of Purine Nucleosides having 2'-Azido and 2'-Amino Functions by Cleavage of Purine Cyclonucleosides," <i>Chem. Pharm. Bull.</i> , 25, 754-760 (1977)
		*	Imazawa and Eckstein, "Facile Synthesis of 2'-Amino-2'-deoxyribofuranosyl Purines," J. Org. Chem. 44:2039-2041 (1979)
		*	Johnson and Benkovic, "Analysis of Protein Function by Mutagenesis," <i>The Enzymes,</i> Vol. 19, 159-211 (1990)
V		*	Karaoglu and Thurlow, "A chemical interference study on the interaction of ribosomal protein L1 from <i>Escherichia coli</i> with RNA molecules containing its binding site from 23S rRNA," <i>Nucleic Acids Research</i> , 19, 5293-5300 (1991)
RC	,   	*	McGee et al., "2'-Amino-2'-deoxyuridine via an Interamolecular Cyclization of a Trichloroacetimidate," J. Org. Chem., 61, 781-785 (1996)

EXAMINER SET SET	Pe.	DATE CONSIDERED  8-13-63	
11-11-11-1			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHNEN HULBERT & BERGHOFF 300 SOUTH WACKER DRIVE CHICAGO, ILLINOIS 60606 TELEPHONE (312) 913-0001

1632



<del></del>		
PL	•	Nefkins et al., "A Simple Preparation of Phthaloyl Amino Acids Via a Mild Phthaloylation," Recl. Trav. Chim. Pays-Bas., 79, 688-698 (1960)
1	*	Robins et al., "Nucleic Acid Related Compounds. 71. Efficient General Synthesis of Purine (Amino, Azido, and Triflate)-Sugar Nucleosides," <i>Nucleosides and Nucleotides</i> 11:821-834 (1992)
	*	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," The Journal of Biological Chemistry 274:21783-21789 (1999)
	*	Sproat et al., "An Efficient Method for the Isolation and Purification of Oligoribonucleotides," Nucleosides & Nucleotides 14:255-273 (1995)
	*	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" Science 261:1004-1288 (1993)
	*	Stein et al., "A Specificity Comparison of Four Antisense Types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," <u>Antisense &amp; Nucleic Acid Drug Development</u> 7:151-157 (1997)
	*	Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," Cell 63:601-608 (1990)
	*	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," Proc. Natl. Acad. Sci. USA 90:1300-1304 (1993)
	*	Tsai et al., "In vitro selection of an RNA epitope immunologically cross-reactive with a peptide," Proc. Natl. Acad. Sci. USA 89:8864-8868 (1992)
	*	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethoionine tRNA," J. Am. Chem. Soc. 109:7845-7854 (1987)
PL	*	Usman et al., "Hammerhead ribozyme engineering," Current Opinion in Structural Biology 1:527-533(1996)

01/11/02

	<del></del>	
EXAMINER		DATE CONSIDERED
Makine	1007	8-13-67
11000		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)

U.S. Department of Commerce Patent and Trademark Office

**Atty. Docket No.** MBHB00,716-D RPI NO. 600.016

**Serial No.** 10/043,951

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(Use several sheets if necessary RECEIVED

MAY 0 6 2002

TECH CENTER 1600/2900

Applicant:

Beigelman, et al.

Filing Date: 01/11/02

**Group:** 1632

PL	•	Usman and Stinchcomb, "Design, Synthesis and Function of Therapeutic Hammerhead Ribozymes," Nucleic Acids and Molecular Biology 10:243-264 (1996)
	*	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <u>TIBS</u> 17:334-339 (1992)
	*	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," Nucleic Acids Syposium Series 31:163-164 (1994)
	*	Vargeese et al., "Efficient activiation fo nucleoside phosphoramidites with 4,5-dicyanoimidazole during oligonucleotide synthesis," <i>Nucleic Acids Research</i> , 26, 1046-1050 (1998)
V	*	Verheyden et al., "Synthesis of Some Pyrimidine 2'-Amino-2'-deoxynucleosides," J. Org. Chem. 36:250-254 (1971)
12	*	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," Nucleic Acids Research 23(14):2677-2684 (1995)

EXAMINER	DATE CONSIDERED
Matintal Inc	8-17-13

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.